Economic and humanistic burden of fibromyalgia in the USA

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 6, Issue 3, 2006, Pages 303-314

  Evans, Christopher J ^a   Parthan, Anju ^b   Le, Kim ^c  

^a Mapi Values ^*  (United States)

^b MAPI VALUES   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Cost of illness; Fibromyalgia; Patient reported outcomes; Quality of life

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CARBIDOPA; CELECOXIB; CLONAZEPAM; CODEINE; CYCLOBENZAPRINE; DOXEPIN; DULOXETINE; ETODOLAC; FLUOXETINE; HYDROCODONE; LEVODOPA; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE; PARACETAMOL; PAROXETINE; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; ZALEPLON; ZOLPIDEM TARTRATE;

AGE; BLADDER IRRITATION; CHRONIC DISEASE; CHRONIC RHINITIS; COGNITIVE DEFECT; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DRUG DOSE REGIMEN; DRUG MECHANISM; ECONOMIC EVALUATION; EXERCISE; EYE DISEASE; FATIGUE; FIBROMYALGIA; HEALTH CARE COST; HEALTH ECONOMICS; HEARING DISORDER; HEART PALPITATION; HUMAN; JOINT SWELLING; LOW DRUG DOSE; MEDICAL RESEARCH; MOOD DISORDER; MORNING STIFFNESS; MUSCLE WEAKNESS; PAIN; PARESTHESIA; PREVALENCE; QUALITY OF LIFE; REVIEW; SEX DIFFERENCE; SLEEP DISORDER; UNITED STATES; VESTIBULAR DISORDER;

EID: 33745598519     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.6.3.303     Document Type: Review

References (57)

1. Klippel JH, Freundlich B, Leventhal L. Primer on rheumatic diseases. Arthritis Foundation 11, 123-127 (1998).
2. Hudson JI, Goldenberg DL, Pope HG Jr, Keck PE Jr, Schlesinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am. J. Med. 92, 363-367 (1992).
3. Winfield JB. Pain in fibromyalgia. Rheum. Dis. Clin. North Am. 25(1), 55-79 (1999).
4. Geisser ME, Casey KL, Brucksch CB, Ribbens CM, Appleton BB, Crofford LJ. Perception of noxious and innocuous heat stimulation among healthy women and women with fibromyalgia: association with mood, somatic focus, and catastrophizing. Pain 102, 243-250 (2003).
5. Petzke F, Clauw DJ, Ambrose K, Khine A, Gracely RH. Increased pain sensitivity in fibromyalgia: effects of stimulus type and mode presentation. Pain 105, 403-413 (2003).
6. Bendtsen L, Norregaard J, Jensen R, Olesen J. Evidence of qualitatively altered nociception in patients with fibomyalgia. Arthritis Rheum. 40(1), 98-102 (1997).
7. Friedberg F, Jason LA. Chronic fatigue syndrome and fibromyalgia: clinical assessment and treatment. J. Clin. Psychol. 57(4), 433-455 (2001).
8. Burckhardt CS, Goldenberg D, Crofford L et al. Guideline for the management of fibromyalgia syndrome pain in adults and children. APS Clinical Practice Guidelines Series, No. 4. American Pain Society, Glenview, IL, USA (2005).
9. Wolfe F, Smythe H, Yunus M et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum. 33(2), 160-172 (1990).
10. Goldenberg D, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 292(19), 2388-2395 (2004).
11. Lash AA, Ehrlich-Jones L, McCoy D. Fibromyalgia: evolving concepts and management in primary care settings. Medsurg. Nurs. 12(3), 145-190 (2003).
12. O'Malley PG, Balden E, Tomkins G, Santoro J, Kroenke K, Jackson JL. Treatment of fibromyalgia with antidepressants: a meta-analysis. J. Gen. Intern. Med. 15, 659-666 (2000).
13. Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 41 (2), 104-113 (2000).
14. Dayer P, Collart L, Desmeules J. The pharmacology of tramadol. Drugs 47(Suppl. 1), 3-7 (1994).
15. Gobbi M, Mennini T. Release studies with rat brain cortical synaptosomes indicate that tramadol is a 5-hydroxytryptamine uptake blocker and not a 5-hydroxytryptamine releaser. Eur. J. Pharmacol. 370, 23-26 (1999).
16. Sagata K, Minami K, Yanagihara N et al. Tramadol inhibits norepinephrine transporter function at desipramine-binding sites in cultured bovine adrenal medullary cells. Anesth. Analg. 94, 901-906 (2002).
17. Backonja M, Beydoun A, Edwards KR et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. J. Am. Med. Assoc. 280 (21), 1831-1836 (1998).
18. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch. Intern. Med. 159(16), 1931-1937 (1999).
19. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. J. Am. Med. Assoc. 280(21), 1837-1842 (1998).
20. Rossy LA, Buckelew SP, Hagglund KJ et al. A meta-analysis of fibromyalgia treatment interventions. Ann. Behav. Med. 21, 18091 (1999).
21. Sim J, Adams N. Systematic review of randomized controlled trials of nonpharmacological interventions in fibromyalgia. Clin. J. Pain 18, 324-336 (2002).
22. Wolfe F, Ross K, Anderson J, Russell J, Herbert L. The prevalence of fibromyalgia in the general population. Arthritis Rheum. 38, 19-28 (1995).
23. White K, Speechley M, Harth M, Ostbye T. The London Fibromyalgia epidemiology study: the prevalence of fibromyalgia in London Ontario. J. Rheumatol. 26, 1570-1576 (1999).
24. Leslie A, Burke M, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and tempromandibular disorder. Arch. Intern. Med. 16, 221-227 (2000).
25. Wolfe F, Anderson J, Harkness D et al. A prospective, longitudinal, multicenter study of service utilization. Arthritis Rheum. 40, 1560-1570 (1997).
26. Bernatsky S, Dobkin P, Civita M, Penrod J. Comorbidity and physician use on fibromyalgia. Swiss Med. Wkly 135, 76-81 (2005).
27. Greenberg P, Leong S, Birnbaum H, Robinson R. The economic burden of depression with painful symptoms. J. Clin. Psychiatry 64 (Suppl.), 17-23 (2003).
28. Robinson R, Birnbaum H, Morley M, Sisitsky T, Greenberg P, Wolfe F. Depression and fibromyalgia: treatment and costs when diagnosed separately or concurrently. J. Rheumatol. 31, 1621-1629 (2004).
29. Robinson R, Birnbaum H, Morley M, Sisitsky T, Greenberg P, Claxton A. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J. Rheumatol. 30, 1318-1325 (2003).
30. Wolfe F, Michaud K. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromyalgia. J. Rheumatol. 31, 695-700 (2004).
31. Whalen H, Cronan T, Bigatti S. Factors associated with healthcare costs in women with fibromyalgia. Am. J. Manag. Care 7, SP39-SP47 (2001).
32. Bigatti S, Cronana. An examination of the physical health, health care use, and psychological well-being of spouses of people with fibromyalgia syndrome. Health Psychol. 21, 157-166 (2002).
33. Lightfoot R, Luft B, Rahn D et al. Empirical parental antibiotic treatment of patients with fibromyalgia and fatigue and a positive serologic result for Lyme disease. A cost-effectiveness analysis. Ann. Intern. Med. 119, 503-509 (1993).
34. Burckhardt CS, Clark SR, Bennett RM. Fibromyalgia and quality of life: a comparative analysis. J. Rheumatol. 20, 475-479 (1993).
35. Gaston-Johansson F, Gustafsson M, Felldin R, Sanne H. A comparative study of feelings, attitudes and behaviors of patients with fibromyalgia and rheumatoid arthritis. Soc. Sci. Med 31, 941-947 (1990).
36. Bernard A, Prince A, Edsall P. Quality of life issues for fibromyalgia patients. Arthritis Care Res. 13(1), 42-50 (2000).
37. Reisine S, Fifiel J, Walsh SJ, Feinn R. Do employment and family work affect the health status of women with fibrornyalgia. J. Rheumatol. 30(9), 2045-2053 (2003).
38. Paulson M, Norberg A, Danielson E. Men living with fibromyalgia-type pain: experiences as patients in the swedish health care system. J. Adv. Nurs. 40(1), 87-95 (2002).
39. Bernard AL, Prince A, Edsall P. Quality of life issues for fibromyalgia patients. Arthritis Care Res,. 13(1), 42-50 (2000).
40. Martinez JE, Berraz MB, Sato EI, Atra E. Fibromyalgia versus rheumatoid arthritis: a longitudinal comparison of the quality of life. J. Rheumatol. 22(2), 270-274 (1995).
41. Valim V, Oliveira L, Suda A et al. Aerobic fitness effects in fibromyalgia. J. Rheumatol. 30(5), 1060-1069 (2003).
42. Affleck G, Urrows S, Tennen H, Higgins P, Abeles M. Sequential daily relations of sleep, pain intensity, and attention to pain among women with fibromyalgia. Pain 68(2-3), 363-368 (1996).
43. Soderberg S, Lundman B, Norberg A. The meaning of fatigue and tiredness as narrated by women with fibromyalgia and healthy women. J. Clin. Nurs. 11 (2), 247-255 (2002).
44. Cudney SA, Butler MR, Weinert C, Sullivan T. Ten rural women living with fibromyalgia tell it like it is. Holist. Nurs. Pract. 16(3), 35-45 (2002).
45. Meenan R, Mason J, Anderson J et al. AIMS2: the content and properties of a revised and expanded Arthritis Impact Measurement Scales health status questionnaire. Arthritis Rheum. 35, 1-10 (1992).
46. McConnell S, Kolopack P, Davis AM. The Western Ontario and McMAster Universities Index (WOMAC): a review of its utility and measurement properties. Arthritis Rheum. 45(5), 453-461 (2001).
47. Wolfe F, Kong SX. Rasch analysis of the Western Ontario MacMaster Questionnaire (WOMAC) in 2205 patietns with osteoarthritis, rheumatoid arthritis and fibromyalgia. Ann. Rheum. Dis. 58(9), 563-568 (1999).
48. Bellany N, Buchanan WW, Goldsmith CH et al. Validation study of WOMAC: a health status instrument for measuring clinically Important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J. Rheumatol. 15, 1833-1840 (1988).
49. Wright JG, Young NL. A comparison of different indices of responsiveness. J. Clin. Epidemiol. 50(3), 239-246 (1997).
50. Brazier JE, Harper R, Munro J et al. Generic and condition-specific outcome measures for people with osteoarthritis of the knee. Rheumatology 38(9), 870-877 (1999).
51. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. J. Rheumatol. 18(5), 728-733 (1991).
52. Wolfe F, Hawley DJ, Goldenberg DL, Russell J, Buskila D, Neumann L. The assessment of functional impairment in fibromyalgia (FM): Rasch analyses of 5 functional scales and the development of the FM Health Assessment Questionnaire. J. Rheumatol. 27(8), 1989-1999 (2000).
53. Zachrisson O, Regland B, Jahreskog M, Jonsson M, Kron M, Gottfries CG. Treatment with Staphylococcus toxoid in fibromyalgia/chronic fatigue syndrome - a randomized controlled trial. Eur. J. Pain 6(6), 455-466 (2002).
54. Ware JE, Sherbourne CD. The MOS 35-Item Short-Form Health Survey (SF-36). I. conceptual framework and item selection. Med. Care 30(6), 473-483 (1992).
55. McHorney CA, Ware JE Jr, Razcek AE. The MOS 36-Item Short-Form Health Survey (SF-36):II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med. Care 31 (3), 427-463 (1993).
56. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36): III.Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med. Care 32(1), 40-66 (1994).
57. Dean BB, Aguilar D, Barghout V et al. Impairment in work productivity and health-related quality of life in patients with irritable bowel syndrome. Am. J. Manag. Care 11, S17-S26 (2005).